Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Strati · SciRah

Researcher profile · Semantic Scholar

P. Strati

Share profile

P. Strati — researcher profile on SciRah

h-index: 43
Works: 405
Citations: 6,637

Most-cited papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Armin Ghobadi, Veronika Bachanova, K. Patel, Jae H. Park +13 more
2025The Lancet123 citations Open access
Semantic Scholar
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Rishika Prasad, Abdur Rehman, Lubna Rehman, F. Darbaniyan +46 more
2024Blood61 citations Open access
Semantic Scholar
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.
Laura Samples, Hossein Sadrzadeh, M. Frigault, C. Jacobson +34 more
2025Blood19 citations
Semantic Scholar
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study.
P. Strati, Januario E. Castro, Aaron Goodman, V. Bachanova +12 more
2025The Lancet Haematology19 citations
Semantic Scholar
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.
C. Pinnix, B. Dabaja, J. Gunther, P. Fang +14 more
2024JAMA Oncology18 citations Open access
Semantic Scholar
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
G. S. Manzar, C. Pinnix, S. Dudzinski, K. Marqueen +18 more
2025Frontiers in Immunology15 citations Open access
Semantic Scholar
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma
P. Strati, Lei Feng, A. Tyshevich, D. Shavronskaya +15 more
2025Clinical Cancer Research13 citations
Semantic Scholar
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy
James Long, Rishab Prakash, P. Edelkamp, M. Knafl +19 more
2025JAMA Network Open12 citations Open access
Semantic Scholar
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas
D. Chihara, Raphael Steiner, R. Nair, Lei Feng +16 more
2025Blood Advances10 citations Open access
Semantic Scholar
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
P. Strati, Lei Feng, J. Westin, R. Nair +15 more
2025Nature Communications7 citations Open access
Semantic Scholar
Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study
J. Sharp, P. Strati, Subodh Bhatta, Jennifer J. Huang +25 more
2026Blood Advances6 citations Open access
Semantic Scholar
Abstract CT037: A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma
P. Strati, Lei Feng, D. Chihara, J. Westin +8 more
2024Cancer Research5 citations
Semantic Scholar
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Neha Akkad, Lei Feng, J. Westin, F. Hagemeister +17 more
2025Blood Advances4 citations Open access
Semantic Scholar
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
P. Strati, Amanda Brandt, Anath C. Lionel, J. Henderson +10 more
2025Journal for ImmunoTherapy of Cancer4 citations Open access
Semantic Scholar
Gastrointestinal toxicities of proteasome inhibitor therapy
J. Shah, Samanthika S. Devalaraju, Elliot Baerman, I. Lee +10 more
2024Journal of Cancer Research and Clinical Oncology4 citations Open access
Semantic Scholar
Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions
Stefania Fiorcari, P. Strati, Elisabetta Dondi
2024Frontiers in Immunology4 citations Open access
Semantic Scholar
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events
E. Derenzini, A. Gibb, M. Kwiatek, P. Strati
2025Leukemia and Lymphoma3 citations Open access
Semantic Scholar
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Brian T. Hess, A. Moskowitz, James A. Davis, P. Strati +19 more
2025Haematologica3 citations Open access
Semantic Scholar
Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
Sushanth Gouni, Anath C. Lionel, Lei Feng, Charles Gaulin +19 more
2024Blood3 citations
Semantic Scholar
Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial
A. Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler +11 more
2024EClinicalMedicine3 citations Open access
Semantic Scholar
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial
P. Strati, Lori A. Leslie, P. Shiraz, L. Budde +11 more
2026Nature Cancer2 citations Open access
Semantic Scholar
Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study
Neha Venkatesh, Kevin Milligan, Juli Parrish, Yun Qing +6 more
2026eJHaem2 citations Open access
Semantic Scholar
A Rare Case of Cutaneous Crystal‐Storing Histiocytosis With Kappa Light Chain Restriction and Unusual BCL6 Expression
Liangli Wang, J. Curry, Julia Dai, Daniel H. Wang +5 more
2026Journal of cutaneous pathology2 citations Open access
Semantic Scholar
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma.
T. Zhuang, Chen Zhang, P. Strati
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial
Mark P. Hamilton, A. Al Zaki, Lei Feng, Z. Hunzeker +9 more
2025Blood2 citations
Semantic Scholar
Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma
R. Shah, Xiao-Wen Sun, Lei Feng, Anath C. Lionel +15 more
2025Blood2 citations
Semantic Scholar
Zanubrutinib is active for the treatment of relapsed primary vitreoretinal lymphoma
A. L. Chaudhry, Patricia Chévez-Barrios, P. Strati
2025Leukemia and Lymphoma2 citations
Semantic Scholar
Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
C. Strouse, Umar Farooq, R. Shouval, Anusha Vallurupalli +15 more
2024Blood2 citations
Semantic Scholar
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
P. Fang, S. Noticewala, Susan Y. Wu, J. Gunther +16 more
2024Advances in Radiation Oncology2 citations Open access
Semantic Scholar
Ciltacabtagene Autoleucel Immune Effector Cell Enteritis/Colitis Is Driven By Persistent Clonal CAR+ T-Cells.
Mark P. Hamilton, Sharlene Dong, Tania P. Sainz, Aniruddha Mundhada +21 more
2026Transplantation and Cellular Therapy1 citations
Semantic Scholar
Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.
Dai Chihara, Ayushi Chauhan, Ruitao Lin, A. Mason +13 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy
Andrew G. Kuang, Malek Shatila, J. Shah, Nitish Mittal +8 more
2026Therapeutic Advances in Medical Oncology1 citations Open access
Semantic Scholar
Activity of Autologous Anti-CD19 Chimeric Antigen Receptor T-cell Therapy in CD19-Negative Large B-cell Lymphoma: A Cell Therapy Consortium Real World Experience
Chen Zhang, Xiao-Wen Sun, Lei Feng, David L. Porter +11 more
2026Transplantation and Cellular Therapy1 citations
Semantic Scholar
Assessing patient perspectives on enrollment in lymphoma clinical trials
Neha Akkad, Min-Xing Chen, S. Nguyen, Alexis Romero +11 more
2026Cancer1 citations Open access
Semantic Scholar
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
A. Danilov, Catherine C. Coombs, Tycel J. Phillips, J. Allan +12 more
2026Cancer1 citations
Semantic Scholar
Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma
R. Shah, R. Lin, A. Mason, L. Johnson +11 more
2025Blood1 citations
Semantic Scholar
A PHASE II STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED INDOLENT B‐CELL LYMPHOMA
P. Strati, L. Feng, L. Malpica, J. Westin +14 more
2025Hematological Oncology1 citations
Semantic Scholar
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Muhammad Bilal Abid, Lei Feng, Amy A. Ayers, V. Leautaud +21 more
2025Blood1 citations
Semantic Scholar
Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience
Chen Zhang, Xiao-Wen Sun, Lei Feng, David Porter +11 more
2025Blood1 citations
Semantic Scholar
Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients
K. Huebel, P. Strati, L. Sehn, Julie Wu +3 more
2025Blood1 citations
Semantic Scholar
Abstract CT144: Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma
P. Strati, Eva Gonzalez-Barca, Daniel Morillo, Sairah Ahmed +10 more
2024Cancer Research1 citations
Semantic Scholar
Intratumoral Cellular Therapy with Autologous Activated M1 Sirpα-Low Macrophages In Non-Hodgkin Lymphoma: Clinical Results from a First-In-Human Phase 1 Study
P. Strati, T. Feldman, Koby Kidder, Devika Schirloff +4 more
2026Transplantation and Cellular Therapy0 citations
Semantic Scholar
Abstract A041: Prognostic significance of post-CAR-T macrocytosis in large B-cell lymphoma
S. Tantawy, Mark P. Hamilton, D. Chihara, L. Fayad +18 more
2026Blood Cancer Discovery0 citations
Semantic Scholar
Real World Experience of Anakinra for the Treatment of Corticosteroids-Refractory Neurotoxicity in Large B-cell Lymphoma
Sara El Mustapha, R. Shah, Xiao-Wen Sun, Lei Feng +16 more
2026International Journal of Cancer Care and Delivery0 citations Open access
Semantic Scholar
Real World Experience of Anakinra for the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma
R. Shah, Xiao-Wen Sun, Lei Feng, Anath C. Lionel +15 more
2026Transplantation and Cellular Therapy0 citations
Semantic Scholar
Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma
Z. Hunzeker, F. J. de la Rosa, A. Tyshevich, D. Shavronskaya +7 more
2026British Journal of Haematology0 citations Open access
Semantic Scholar
Baseline Physical Function Predicts Toxicity Outcomes after Chimeric Antigen Receptor T-cell Therapy in Non-Hodgkin Lymphoma
R. Shah, Zhiping Luo, R. Fontillas, Betty Holder +15 more
2026Transplantation and Cellular Therapy0 citations
Semantic Scholar
Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.
P. Strati, D. Chraniuk, E. González Barca, Sairah Ahmed +4 more
2026Blood Advances0 citations Open access
Semantic Scholar
Impact of Putative Cell of Origin on CD19+CAR-T Outcomes in Patients with Large B-cell Lymphoma
M. Abid, Lei Feng, Amy A. Ayers, V. Leautaud +23 more
2026Transplantation and Cellular Therapy0 citations
Semantic Scholar
Disease Control Following Radiotherapy for Limited-Site Relapse of Follicular Lymphoma
P. Patel, J. Gunther, S.-Y. Wu, D. Chihara +16 more
2026International Journal of Radiation Oncology, Biology, Physics0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Neelapu×23
Invite
S. Neelapu — researcher profile on SciRah
Sairah Ahmed×22
Invite
Sairah Ahmed — researcher profile on SciRah
J. Westin×17
Invite
J. Westin — researcher profile on SciRah
L. Nastoupil×13
Invite
L. Nastoupil — researcher profile on SciRah

×12

Invite

Lei Feng — researcher profile on SciRah

Invite

D. Chihara — researcher profile on SciRah

Invite

R. Nair — researcher profile on SciRah

Invite

C. Flowers — researcher profile on SciRah

Invite

C. Nze — researcher profile on SciRah

Anath C. Lionel×9

Invite

Anath C. Lionel — researcher profile on SciRah

Invite

L. Fayad — researcher profile on SciRah

Invite

E. Shpall — researcher profile on SciRah